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ABSTRACT:
Purpose: MET alterations including amplifications and nucleotide variations have 
been associated with resistance to therapy and aggressive clinical behavior. 
Experimental Design: The medical records of patients presenting to the 
University of Texas MD Anderson Cancer Center Phase I Clinic with relapsed or 
metastatic ovarian cancers and known MET nucleotide variation or amplification 
status were reviewed retrospectively (n=178). Categorical and continuous clinical and 
molecular characteristics were compared using Fisher’s exact and Wilcoxon rank-sum 
tests, respectively. Univariate and multivariate survival were assessed via Kaplan-
Meier and Cox regression analysis, respectively. 
Results: MET amplification occurred in 4 (3.5%) of 113 patients, whereas 
nonsynonomous nucleotide variations were present in 9 (7.4%) of 122 patients. 
No patients exhibited concomitant amplification and variation. MET variations were 
observed only in white women with high-grade ovarian tumors, whereas amplifications 
were observed in both black and white women with high-grade serous ovarian primary 
tumors. No patients (n=4) exhibiting a MET alteration achieved an objective response 
when treated on a c-Met inhibitor phase I trial. In addition, ovarian cancer patients 
treated with a c-Met inhibitor with multikinase activity trended towards a longer 
time-to-failure compared with those treated with a c-Met-specific inhibitor (median: 
1.5 vs. 4.5 months, p=0.07).
Conclusions: MET alterations occur in a minority of patients with ovarian cancer. 
c-Met inhibitors with multikinase activity may exhibit less activity in ovarian cancer 
than c-Met specific drugs. These findings warrant further investigation.
INTRODUCTION
The c-Met tyrosine kinase receptor (TKR), upon 
activation by its cognate antigen, hepatocyte growth factor 
(HGF), generates proliferation, migration, and survival 
signals in numerous cancers[1, 2]. This signaling cascade 
parallels, and at times can supplement, the activity of 
other oncogenic TKRs. As a result, the c-Met pathway has 
emerged as a resistance pathway in therapies targeting the 
epidermal growth factor receptor (EGFR)[3, 4], B-Raf[5], 
and vascular endothelial growth factor receptor (VEGFR)
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[6], among others. Various MET alterations, including 
amplification and nucleotide variations, have been 
described and are associated with resistance to therapy 
and aggressive clinical behavior[3, 4, 7]. The pathologic 
implications of this important receptor has prompted 
the development of c-Met inhibitors, many of which 
are currently undergoing early phase trials in various 
cancers[2]. 
Ovarian, primary peritoneal, and fallopian tube 
cancers have similar ontological origins and clinical 
presentations. Their aggressive metastatic behavior 
and generally poor prognosis has prompted interest in 
developing therapies with TKR inhibitors, including 
those targeting EGFR and c-Met[8, 9]. However, outside 
of bevacizumab, targeted therapies tested in early clinical 
trials have yet to gain widespread clinical success[8]. 
Despite understanding of the intrinsic biology of the c-Met 
pathway and its documented role in drug resistance, no 
substantive clinical series have assessed the effect of 
MET variations and amplifications in this disease[10-12]. 
We, therefore, investigated the clinical and molecular 
characteristics of patients with ovarian cancers referred to 
our Phase I Clinical Trials Program and their response to 
treatment on a phase I c-Met inhibitor trial.
RESULTS
Patient Characteristics
One-hundred-and-seventy-eight patients met study 
inclusion criteria, of whom 122 and 113 were tested 
for MET variations and amplification, respectively. 
Fifty-seven patients were tested for both variation and 
amplification. MET nucleotide variations were detected 
in 9 patients (7.4%): 6 with N375S and 3 with T1010I 
nonsynonomous variations. MET amplification was 
detected in 4 patients (3.5%), amplification gene copy 
numbers (in relation to CEP7) were 2.12, 2.27, 2.55, and 
2.78. No patients exhibited concomitant MET nucleotide 
variation and amplification.
Characteristics associated with MET aberrations
No significant differences were noted between 
patient characteristics when stratified by MET variation 
or amplification status (all p>0.05). MET variations were 
detected only in white women with high-grade primary 
ovarian tumors (Tables 1 and 2). The histology of cancers 
with MET variations was predominately serous (74%), 
with one patient each having carcinosarcoma and clear cell 
carcinoma (Table 1). The median numbers of metastatic 
sites among patients with MET variations compared with 
those without were both 2. Among patients with MET 
variations, 44% had liver metastasis, a rate similar to 
liver metastasis in patients without MET variation (34%). 
Concomitant mutations included KRAS, BRCA1, ARID1A, 
and TP53 were identified in 1, 1, 1, and 2 patients, 
respectively. In addition, one patient had concomitant 
PTEN loss and another had weak PTEN staining (Table 
2).  Of note, no ovarian cancer patients within any stratum 
exhibited ALK rearrangement, BRAF, EGFR, or KIT 
mutations. 
MET amplification occurred only in women with 
high grade serous ovarian cancer (Tables 1 and 2).  Three 
out of 4 women were white and 1 was black. Similar to 
patients with MET variations, MET amplified patients had 
a median of 2 metastatic sites, with 1 patient exhibiting 
liver metastasis. No concomitant mutations were observed 
in MET amplified patients except for in 2 patients who 
exhibited loss of PTEN protein expression. 
MET alterations and survival
OS in patients with a MET aberration (either 
variation or amplification, n=13) was compared with 
that of patients known to be negative for any aberrations 
(n=50). There was no significant different in median 
survival in patients exhibiting MET alterations (Fig. 1; 
HR=1.6, p=0.25). Patients with MET alterations trended 
towards worse OS in multivariate analysis (HR=1.8, 
p=0.13) when adjusting for histology (serous vs. other), 
age (≥60 vs. <60), and number of prior therapies (>3 vs. 
≤3).
Treatment with c-Met inhibitors
All patients treated on a Phase I c-Met inhibitor 
clinical trial had a diagnosis of ovarian cancer. This 
included 4 patients with MET nucleotide variation and one 
with MET amplification (Table 3). No patients with a MET 
alteration achieved an objective response. 
Among all patients with ovarian cancer treated on a 
c-Met inhibitor trial, 5 out of 18 (28%) exhibited a partial 
response (PR) or stable disease (SD) lasting ≥6 months. Of 
these, 2 of 18 patients (11%) achieved a best response of 
PR (Fig. 2, Table 4). Prolonged SD lasting ≥6 months was 
achieved in 3 patients with TTFs lasting 6, 7.8, and 29.8 
months. The median TTF in patients treated with a c-Met-
specific inhibitor (1.5 months, range 0.4-7.8 months, 
n=9) was less than patients treated with a multikinase 
inhibitor (n=8) or a multikinase inhibitor combined with 
a VEGFR2 inhibitor (n=1)(4.5 months, range 1.2-29.8 
months). This difference trended towards significance 
(p=0.07). Interestingly, among 3 patients with known 
TP53 mutations treated on a c-Met inhibitor trial, the 2 
patients treated with a c-Met inhibitor with multikinase 
activity exhibited objective responses, while the one 
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Table 1: Demographic characteristics and metastatic sites in patients stratified by MET nucleotide variation 
and amplification status
Characteristic Wild-Type (n=113) Variation (n=9) Not amplified (n=109) Amplified (n=4)
Age Diagnosis: Median (Q3-Q1) 54 (47-61) 54 (46-56) 54 (47-61) 60 (54-67)
Prior Therapies: Median (Q3-Q1) 3 (2-5) 3 (2-5) 3 (2-5) 2 (1-5)
Diagnosis
Fallopian 11 (9%) 0 1 (1%) 0
Peritoneal vs. Ovarian 2 (2%) 0 1 (1%) 0
Peritoneal 5 (4%) 0 2 (2%) 0
Ovarian 95 (84%) 9 (100%) 105 (96%) 4 (100%)
Ethnicity
Asian/AM-indian 2 (2%) 0 2 (2%) 0
Black 3 (3%) 0 4 (4%) 1 (25%)
Hispanic 11 (10%) 0 9 (8%) 0
White 97 (86%) 9 (100%) 94 (86%) 3 (75%)
Histology
Serous 75 (66%) 7 (78%) 70 (64%) 4 (100%)
Endometrioid 5 (4%) 0 5 (5%) 0
Clear Cell 9 (8%) 1 (11%) 13 (12%) 0
Mucinous 0 0 2 (2%) 0
Mixed 11 (10%) 0 13 (12%) 0
Carcinoma NOS 2 (2%) 0 1 (1%) 0
Carcinosarcoma 5 (4%) 1 (11%) 1 (1%) 0
Granulosa 6 (5%) 0 4 (4%) 0
Metastasis
# Met Sites: Median (Q3-Q1) 2 (2-3) 2 (2-4) 2 (2-3) 2 (2-3)
Liver 39 (34%) 4 (44%) 48 (44%) 1 (25%)
Lungs 23 (20%) 3 (33%) 20 (18%) 0
Bone 6 (5%) 0 7 (6%) 0
CNS 4 (4%) 0 4 (4%) 0
Peritoneum 102 (90%) 8 (89%) 97 (89%) 4 (100%)
Other Sites 83 (73%) 7 (78%) 81 (74%) 3 (75%)
Abbreviations: (Q3-Q1) = 75th to 25th percentile, AM-indian = American indian, NOS = not otherwise specified, Met = metastatic, CNS = 
central nervous system.
Figure 1: Kaplan-Meier plot of overall survival in ovarian cancer patients with MET variation or amplification 
(dashed-black line) compared with patients without MET variation or amplification (solid-gray line).
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Table 2: Histologic and genetic characteristics in patients stratified by MET nucleotide variation and 
amplification status
Characteristic No Variation (n=113) Variation (n=9) Not amplified (n=109) Amplified (n=4)
HER2 amplification 4/73 (5%) 0/5 3/71 (4%) 0/2
ALK rearrangement 0/36 0/2 0/38 0/1
PIK3CA mutation 8/109 (7%) 0/9 10/104 (10%) 0/4
KRAS mutation 11/105 (10%) 1/8 (13%) 7/90 (8%) 0/3
EGFR mutation 0/86 0/4 0/76 0/3
TP53 mutation* 34/69 (49%) 3/4 (75%) 18/33 (5%) 0/1
BRAF mutation 0/103 0/8 0/82 0/3
NRAS mutation 2/96 (2%) 0/3 0/45 0/2
KIT mutation 0/83 0/3 0/48 0/1
% ER+: median (Q3-Q1) 70 (20-90) N=86 30 (20-80) N=7 70 (5-90) N=81 35 (13-65) N=4
% PR+: median (Q3-Q1) 10 (5-30) N=50 N=0 5 (1-38) N=28 3 (1-5) N=2
PTEN
Loss 7/77 (9%) 1/8 (13%) 4/81 (5%) 2/4 (50%)
Weak 10/77 (13%) 1/8 (13%) 15/81 (19%) 0/4
No Loss 60/77 (78%) 6/8 (75%) 62/81 (77%) 2/4 (50%)
Grade
Low 9/97 (9%) 0 6/87 (7%) 0
Medium 2/97 (2%) 0 2/87 (2%) 0
High 86/97 (89%) 6/6 (100%) 79/87 (91%) 4/4 (100%)
Heredity
1st Degree 33/113 (29%) 2/9 (22%) 30/109 (28%) 1/4 (25%)
2nd Degree 40/113 (35%) 3/9 (33%) 33/109 (30%) 2/4 (50%)
BRCA1 or 2 mutation 10/31 (32%) 1/2 (50%) 9/28 (32%) 0/2
Numerator within each cell indicates number of patients exhibiting the characteristic while denominator indicates number of patients 
tested
Abbreviations: (Q3-Q1) = 75th to 25th percentile, % ER+ = percent of cell staining positive for estrogen receptor, % PR+ = percent cells 
staining positive for progesterone receptor, 1st Degree = presence of any first degree relative with either breast or ovarian cancer, 2nd 
Degree = presence of any second degree relative with either breast or ovarian cancer
*TP53 testing was conducted by hotspot analysis
Table 3: Histology and mutation status of patients exhibiting MET variation or amplification, and their 
response to c-Met inhibitors
Patient No. Histology Variation/ Copy Number
Concomitant 
Mutations Inhibitor Class Best Response TTF (mo)
MET variation
1 Serous T1010I BRCA1 c-Met specific PD (+29) 1
2 Serous T1010I - - -
3 Serous T1010I TP53 - -
4 Carcinosarcoma N375S - c-Met specific PD (+39) 1.2
5 Clear Cell N375S PTEN loss Multikinase SD (+19) 1.2
6 Serous N375S KRAS Multikinase SD (+16) 1.5
7 Serous N375S TP53 - -
8 Serous N375S - - -
9 Serous N375S TP53, ARID1A - -
MET amplification
10 Serous 2.12 PTEN loss Multikinase PD(*) 2.1
11 Serous 2.27 PTEN loss - -
12 Serous 2.55 - - -
13 Serous 2.78 - - -
Abbreviations: PD = progressive disease, SD = stable disease, TTF = time to failure
*Indicates clinical progressive disease
Oncoscience9www.impactjournals.com/oncoscience
Table 4: Histology, mutation status, and response of ovarian cancer patients treated on a phase I c-Met 
inhibitor trial
Patient
No. Histology
MET Variation/
Amp Other Mutations Inhibitor Class
Best 
Response
TTF 
(mo)
1 Serous Amp- TP53 Multikinase PR (-72) 14
2 Endometroid Var-/Amp- PI3KCA, STK11 Multikinase+VEGFR2 PR (-31) 7**
3 Serous Var-/Amp- TP53 Multikinase SD (-22) 29.8
4 Clear Cell Var- - c-Met specific SD (0) 4.1
5 Clear Cell Amp- HER2 amp c-Met specific SD (0) 7.8
6 Serous Amp- - Multikinase SD (+7) 6
7 Serous Var-/Amp- KRAS, TP53 c-Met specific SD (+12) 2.9
8 Serous N375S/Amp- KRAS c-Met specific SD (+16) 1.5
9 Clear Cell N375S/Amp- PTEN loss Multikinase SD (+19) 1.2
10 Serous Amp- - c-Met specific PD (+20) 1.5
11 Mixed: Serous/Transitional Amp- PI3KCA Multikinase PD (+20) 2.1
12 Mixed: Serous/Epithelial Amp- - c-Met specific PD (*) 2.1
13 Serous 2.18 PTEN loss Multikinase PD (*) 2.1
14 Serous Var- - c-Met specific PD (*) 0.5
15 Serous Amp- - Multikinase PD (+26) 3
16 Serous T1010I/Amp- BRCA1 c-Met specific PD (+29) 1.0
17 Serous Amp- - Multikinase PD (+30) 1.2
18 Carcinosarcoma N375S - c-Met specific PD (+39) 1.2
Abbreviations: AMP = amplified, Amp- = tested, no MET amplification, Var = variation, Var- = tested, no MET nucleotide variation, PD 
= progressive disease, SD= stable disease, amp=amplification, TTF=time-to-failure
*Indicates clinical progressive disease
**Indicates continuation on a c-Met trial
Figure 2: Waterfall graph of ovarian cancer patients treated on a c-Met inhibitor Phase I trial with measurable 
disease by RECIST criteria. Patients exhibiting MET alteration are annotated above the bar with the corresponding variation or 
fold-amplification (in relation to CEP7). Patients treated with a c-Met inhibitor with multikinase activity are displayed with grey bars, 
while those treated with a c-Met specific inhibitor are displayed with black bars. X-axis indicates time-to-failure (months). (*) Indicates 
clinically progressive disease.
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patient who was treated with a c-Met specific inhibitor did 
not  (Table 4). 
DISCUSSION
The literature delineating the prevalence of MET 
amplification and variations in ovarian cancer is sparse. 
Yamato et al. reported on 5 patients, all with clear cell 
histology, identified with MET amplification out of 
195 (2.5%) patients tested[16]. An earlier report using 
Southern blot analysis in 67 patients with ovarian cancer 
found no amplifications[12]. Two other series with 24 and 
65 ovarian cancer patients found the incidence of MET 
variations to be 1 and 0, respectively [10, 11]. The rates 
in our current cohort (nucleotide variations, 7.4%; and 
amplification, 3.5%) are comparable, albeit higher, than 
those reported in previous studies. A possible explanation 
is that our study population consisted entirely of patients 
with metastatic or relapsed disease, which may skew in 
favor of increased rates of MET aberrations. Of note, 
we did not detect any patients with concomitant MET 
amplification and variation. 
The biologic activity of the MET nucleotide 
variations identified here and even whether these specific 
variations represent somatic mutations or germline 
polymorphisms have yet to be fully elucidated[17, 18]. 
The role of MET amplification has been most extensively 
correlated with tumor invasion and aggressive metastatic 
behavior in gastrointestinal malignancies[19, 20]. With 
regard to MET variations, the N375S nonsynonmous 
variation occurs in the extracellular semaphorin domain, 
whereas the activating T1010I variation occurs in the 
juxtamembrane domain[7, 18]. The characteristics and 
clinical behavior of ovarian cancer in patients with MET 
variations have not been thoroughly described. However, 
data in renal cell and lung carcinomas suggest that somatic 
and germline MET polymorphisms may enhance c-Met 
TKR activity and even confer inhibitor resistance[17, 21]. 
This second observation is corroborated by our data, in 
which no patients exhibiting a MET alteration achieved 
an objective response on a c-Met phase I inhibitor trial. 
Another possible explanation for the lack of an observed 
objective response are that most patients in this study 
were enrolled on a Phase I dose escalation trials and may 
not have received an efficacious study drug dose. Few 
preclinical data have tested the efficacy of these inhibitors 
in MET altered patients [22-24] and to our knowledge no 
associated clinical data have been reported. 
A subset of all ovarian cancer patients achieved 
objective responses. Patients treated with a multikinase 
inhibitor trended toward a longer TTF compared with 
those treated with c-Met-specific inhibitors (median 1.5 vs. 
4.5 months, p=0.07). A possible explanation is that activity 
against VEGFR2, a target with known clinical efficacy in 
ovarian cancer[14], may increase therapeutic efficacy. 
Interestingly 2 out of 3 patients exhibiting TP53 mutations 
exhibited objective responses to c-Met inhibitors and 
were both treated using a multikinase inhibitor. As such, 
observed responses may be due to effects on targets 
other than c-Met, including VEGFR2. This hypothesis 
is supported by recent evidence from our group showing 
that TP53 mutations predict responses to anti-VEGFR2 
therapies[25]. In addition, these data also suggests that 
c-Met inhibition may be more clinically efficacious when 
utilized in a supporting role to block resistance pathways 
in other targeted agents rather than being utilized alone[1, 
2, 4]. These data are preliminary findings that warrant 
further investigation in a randomized clinical trial setting. 
We observed no difference in survival in patients 
with a MET alteration versus those without, although 
in multivariate analysis patients with MET alterations 
trending towards a worse OS (HR=1.8, p=0.13). However 
it is possible that separate analyses of MET variations 
and amplifications may yield different results. Due to 
the limited incidence, we did not observe any significant 
differences in the characteristics of patients with MET 
alterations. In addition, a number of concomitant 
mutations were identified in patients harboring MET 
variations, whereas there were none in patients with MET 
amplification other than PTEN loss. 
Outside of limitations inherent to all retrospective 
reviews, the low frequency of MET variations and 
amplifications observed in this study did not provide 
sufficient statistical power to stringently assess 
demographic and patient characteristic differences. MET 
variation testing was also done with some heterogeneity. 
Although the majority of patients were tested at MD 
Anderson core laboratories, a minority was tested 
with outside platforms. In addition, mutations and 
amplifications were often grouped within a single stratum. 
With regard to amplifications, the relatively low gene copy 
numbers found in this study (range 2.12-2.78) may be 
inadequate to exhibit biological differences. Finally, the 
few number of patients, especially MET altered patients, 
treated on c-Met inhibitor phase I trials makes generalizing 
these observations into a larger patient populations 
difficult. However, despite these limitations, to our 
knowledge this is one of the first studies to substantially 
compare the demographic and clinical characteristics of 
ovarian cancer patients with MET altered patients and 
their response to treatment with c-Met inhibitors. The 
findings of this analysis provide insight into the clinical 
characteristics associated with MET alterations and, if 
validated in the prospective setting, may lead to improved 
strategies utilizing c-Met therapies in this prognostically 
poor patient population.
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METHODS
Patients
We retrospectively reviewed the medical records 
of all consecutive patients presenting to our Phase I 
Clinic starting in May 2010 to November 2012 (n=3607). 
Patients presented for treatment of recurrent or metastatic 
disease, usually after multiple prior treatments (range 
0-13). Eligibility criteria for inclusion in this study were a 
histologic diagnosis of ovarian, fallopian tube, or primary 
peritoneal carcinoma and testing for MET nucleotide 
variations and/or amplification (n=178). This study was 
approved by the MD Anderson Institutional Review Board 
and patient confidentiality was maintained following 
Health Insurance Portability and Accountability Act 
guidelines.
Tissue samples and molecular analysis
MET nucleotide variation and amplification status 
were tested using archival formalin-fixed, paraffin-
embedded tissue blocks in addition to biologic material 
from fine needle aspiration biopsies or excised primary 
or metastatic tumors from diagnostic and/or therapeutic 
procedures. Histology was centrally reviewed in the MD 
Anderson Department of Pathology. MET nucleotide 
variations were assessed in several Clinical Laboratory 
Improvement Amendment-certified laboratories using 
a single test or as part of a gene panel. The majority of 
patients (n=160) were analyzed at the MD Anderson core 
laboratories. Of the remaining samples, 15 were tested at 
Knight Diagnostics (Portland, OR), 2 at the Baylor College 
of Medicine (Houston, TX), and 1 using a Foundation 
One platform (Foundation Medicine, Cambridge, MA) as 
previously described[13]. 
MET amplification status was analyzed via 
fluorescence in situ hybridization (FISH) following 
institutional protocols at MD Anderson. Copy numbers 
were expressed as a gene copy number in relation to 
CEP7, a gene located near the centrosome of the same 
chromosome. Gene copy numbers of 2-fold or greater 
were considered amplified.
Treatment and evaluation
All patients were enrolled when possible in a Phase 
I clinical trial(s) judged to be clinically appropriate by 
the patient’s attending physician. Because confidentiality 
agreements with the providing pharmaceutical company 
stipulate that c-Met inhibitor identities cannot be disclosed, 
c-Met agents were classified as being in one of three 
categories: c-Met-specific inhibitor (3 separate trials), 
c-Met inhibitor with multikinase activity (2 separate 
trials), and c-Met inhibitor with multikinase kinase activity 
in combination with a VEGFR2 kinase inhibitor (1 trial). 
All c-Met inhibitors with multikinase activity also targeted 
the VEGFR2 receptor, a molecule associated with known 
clinical efficacy in ovarian cancer[14]. Patients were 
treated until clinical or radiologic disease progression, 
development of unacceptable toxicities or death, clinical 
judgment necessitating patient removal, or withdrawal of 
patient consent. 
Clinical assessments were performed according to 
the specific requirements of individual protocols, typically 
once prior to the initiation of treatment and then at least 
every treatment cycle. Treatment responses were primarily 
assessed using computed tomography scans, magnetic 
resonance imaging, and/or positron emission tomography 
conducted prior to therapy and every 2 cycles thereafter 
(6-8 weeks). Radiographs were read in the Department of 
Radiology at MD Anderson and reviewed by physicians in 
our Phase I Clinical Trials Program. Objective responses 
were determined according to RECSIT 1.0 or 1.1 criteria, 
as specified by individual protocols, and the best responses 
achieved were recorded[15]. 
Statistical Methods
Patient demographics and tumor molecular and 
histologic characteristics were summarized in relation to 
MET nucleotide variation and amplification status. Time 
to treatment failure (TTF) was defined as the time from 
the initiation of therapy to its cessation for any reason. 
Categorical and continuous variables, including TTF and 
stratification by MET alteration were compared utilizing 
Fisher’s exact and Wilcoxon rank-sum tests, respectively. 
Overall survival (OS) was assessed starting from the date 
of the first appointment in the Phase I Clinic using Kaplan-
Meier analysis with comparisons via the partial likelihood 
ratio test. Multivariate and univariate hazard ratios (HR) 
were calculated via Cox regression. Wald p-values were 
reported for multivariate analyses. All tests were two-sided 
when appropriate and considered significant at p<0.05. 
Statistical analyses were performed using SAS version 9.3 
(SAS Institute Inc., Cary, NC).
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